Earnings call transcript: Cooper Companies Q2 2025 shows strong EPS, stock dips

Cooper Companies (COO) reported a solid Q2 2025 earnings, with EPS at $0.96 (beating the $0.9282 forecast) and revenue reaching $1,002 million (exceeding the $995.95 million expectation), driven by a 6% year-over-year revenue increase and 7% organic growth. Despite the earnings beat and a 14% increase in non-GAAP earnings, the company's stock fell 3.78% in aftermarket trading, potentially reflecting investor concerns about revised growth expectations in the contact lens and fertility markets, as well as increased R&D expenses; the company projects FY25 revenue between $4.11 and $4.15 billion and non-GAAP EPS between $4.05 and $4.11, but anticipates a 3% earnings impact from tariffs next fiscal year.

Analysis

Cooper Companies (COO) reported a robust financial performance for Q2 2025, with earnings per share of $0.96 and revenue of $1,002 million, surpassing analyst forecasts of $0.9282 and $995.95 million respectively. This was driven by a 14% year-over-year increase in non-GAAP earnings and a 6% rise in consolidated revenues (7% organic), supported by strong showings in both CooperVision and CooperSurgical segments, notably from daily silicone hydrogel lenses, myopia management solutions, and the office/surgical portfolio. Gross margin improved to 68% from 67.3%, and operating margin reached 24.9%. Despite these positive results and an InvestingPro financial health score of 2.8 out of 5 categorized as 'GOOD', the company's stock declined 3.78% in aftermarket trading. This market reaction likely reflects concerns over revised, lower growth expectations for the broader contact lens and fertility markets, increased R&D expenses which rose 21% in the quarter, and anticipated channel inventory pressures. Management acknowledged these softer market conditions, reducing industry growth forecasts for contact lenses to 4-6% (from 5-7%) and fertility to low single digits, consequently adjusting CooperVision’s organic growth guidance to 6-7% and CooperSurgical’s to 3.5-4.5%. However, the company tightened and raised its overall FY25 revenue guidance to $4.11-$4.15 billion and non-GAAP EPS to $4.05-$4.11, reflecting the Q2 outperformance and favorable currency movements, but also factoring in a $4 million tariff impact for the current fiscal year and a potential 3% pre-mitigation adverse impact on FY26 earnings from tariffs. Management emphasized strong execution in gaining market share, particularly with MiSight (up 35% YoY) and MyDay, and ongoing operational efficiencies, while also noting that channel inventory adjustments and shifts in consumer purchasing behavior, such as buying shorter supplies and destocking of legacy hydrogel lenses, are currently impacting reported revenue growth despite strong underlying fitting activity. The company also repurchased $40.6 million of its stock during the quarter.

Key Decisions for Investors

• Investors should critically evaluate the dichotomy between Cooper's strong Q2 operational performance and raised FY25 guidance against the negative stock reaction, which appears to stem from lowered forward-looking market growth rates in its core segments and identified headwinds like channel inventory adjustments and future tariffs.
• Careful monitoring of channel inventory dynamics, consumer purchasing behavior (e.g., length of supply purchased), and the performance of legacy hydrogel products is crucial, as these factors are currently obscuring stronger underlying demand and fitting trends, particularly in the contact lens market.
• Assess the company's ability to continue gaining market share with key growth drivers like MyDay and MiSight, the latter employing a new free-trial promotional strategy which may temper Q3 revenues before an expected Q4 acceleration, and consider the long-term return on the significant 21% Q2 increase in R&D spending against the backdrop of moderating market growth and the need to mitigate tariff impacts.